Extract from Bell Potter research report of 01/09/23:
The trial is expected to cost MSB in the range of US$6-$9m (mid single digits). BM-CTN
will conduct the adult trial and meet some of the funding requirement.
First patient enrolment is likely in 1QCY24.
Ann: Half Year Report and Accounts (including Appendix 4D), page-18
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.025(2.29%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.13 | $1.05 | $8.152M | 7.517M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 69963 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 73154 | 3 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.07 |
Change
-0.025 ( 2.84 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.13 | $1.05 | 1873215 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| MSB (ASX) Chart |